Omiganan achieves dose-dependant response in rosacea

Canadian drug development firm Migenix says that a Phase II study conducted by its partner, USA-based Cutanea Life Sciences, indicates that omiganan gel brought about a dose-dependant response when used in the treatment of the skin condition rosacea. Specifically, the results showed that the 2.5% formulation reduced the occurrence of disease-associated lesions to a greater extent than the 1% version of the same product.

In the trial, 240 rosacea sufferers were randomized to receive either of the two formulations of omiganan, or the basic vehicle gel used by the product, for a nine-week period. The results showed that the drug was safe and well tolerated at all doses tested. Migenix said that, based on the results, Cutanea is to continue development of the 2.5% strength product, specifically as a treatment for papulopustular rosacea.